<DOC>
	<DOCNO>NCT02756832</DOCNO>
	<brief_summary>The purpose study observe clinical response treatment alogliptin benzoate ( Vipidia ) utilization pattern standard clinical practice .</brief_summary>
	<brief_title>Local , Multicenter , Observational , Non-Interventional Prospective Study Alogliptin Benzoate Participants With Diabetes Mellitus Type 2</brief_title>
	<detailed_description>The drug study study call alogliptin benzoate . Alogliptin benzoate research treat people diabetes mellitus type 2 . This study look glycosylated hemoglobin ( HbA1c ) level dynamic participant diabetes mellitus type 2 . The study enroll approximately 1403 patient . Alogliptin benzoate prescribe physician accordance Russian summary product characteristic ( SmPC ) . This multi-center study conduct Russian Federation . The overall duration study observation approximately 6 month . Participants make multiple visit clinic assign physician accord routine practice , every 3 month .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Alogliptin</mesh_term>
	<criteria>1 . Male female participant ≥ 18 year age ; 2 . Has diagnosis type 2 diabetes mellitus ( T2DM ) 3 . Participants : newly diagnose diabetes mellitus ( DM ) type 2 ( drug naïve ) inadequate glycemic control previously prescribe oral antidiabetic drug . 4 . Vipidia prescribe accord approve label Russian Federation . 5 . The participant 's physician decides prescribe Vipidia : monotherapy part combination therapy . 6 . The participant ( , applicable , participant 's legally acceptable representative ) sign date write , informed consent form prior start data collection . Participant capable understand write informed consent , provide sign write informed consent , agree comply protocol requirement . In case participant blind unable read , inform consent also witness . 1 . Contraindications respective approve Russian summary product characteristic ( SmPC ) ; 2 . In opinion physician , participant reason medical nonmedical character , opinion physician prevent participant participation study ; 3 . Had use Dipeptidyl peptidase4 inhibitor ( DPPIV inhibitor ) Glucagon like peptide1 agonist ( aGLP1 ) within 3 month prior start Vipidia treatment . 4 . Is immediate family member , study site employee , dependent relationship study site employee involve conduct study ( eg , spouse , parent , child , sibling ) may consent duress .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Drug Therapy</keyword>
</DOC>